南非胸科学会儿童、青少年及成人哮喘立场声明
南非胸科学会发布哮喘立场声明,指出全球约10%人口患哮喘,非洲哮喘死亡率上升与SABA过度使用、ICS可及性不足有关,为此成立SA哮喘行动组以改善管理。
要点
- 非洲哮喘死亡率上升,与过度依赖SABA、ICS可及性差及依从性不佳相关。
- SABA过度使用与严重哮喘不良结局相关,应推广含ICS的联合吸入治疗。
- 吸入器推进剂变更为低全球变暖潜势推进剂可能影响治疗可及性。
核心结论
- 非洲哮喘死亡率上升源于照护策略不足、依赖缓解药物和患者依从性差。
- SABA过度使用与严重哮喘疾病负担相关,ICS为基础的控制治疗可及性有限。
研究设计与样本
- 南非胸科学会发布的立场声明,非系统评价或原始研究。
主要发现
- 估计全球10%人口患有哮喘。
- 南非富裕地区儿童哮喘患病率高于较不富裕背景儿童。
- 非洲和东南亚哮喘死亡率上升,而高收入国家下降。
- 吸入器碳足迹及2030年前推进剂变更可能进一步限制治疗可及性。
关键数值与推荐
- 国际推荐的标准治疗为含ICS-长效β2受体激动剂的联合吸入器。
- SABA过度使用和过度依赖与严重哮喘疾病负担相关。
临床怎么用
- 成立南非哮喘行动组,联合医务人员、资助方和政府代表改善哮喘管理。
- 战略计划包括应对SABA过度使用、参与指南制定、提高基本药物可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Afr J Thorac Crit Care Med. 2026 Mar 31;32(1):e4339. doi: 10.7196/AJTCCM.2026.v32i1.4339. eCollection 2026. ABSTRACT It is estimated that 10% of the global population has asthma. Low- and middle-income countries typically struggle to provide affordable asthma care, including access to combination (inhaled corticosteroid (ICS)-long-acting beta-2-agonist) inhalers currently recommended internationally as standard of care. In South Africa (SA), a study found higher asthma prevalence among children in affluent areas compared with those from less affluent backgrounds. Asthma mortality is increasing in Africa and Southeast Asia compared with declines in high-income countries. This mortality crisis stems from inadequate care strategies, reliance on reliever therapy, and patient non adherence. Overuse of and over-reliance on short-acting beta-2-agonist (SABA) inhalers worsen outcomes, with severe morbidity related to asthma. Limited access to and use of ICS-based controller therapy worsen outcomes. The carbon footprint of inhalers and proposed changes in propellants to those with lower global warming potential due to be phased in by 2030 may further limit treatment availability in the near future. To combat these challenges, the SA Asthma Action Group has been formed, bringing together healthcare professionals, funders and government representatives to improve asthma management. The strategic plan of this group is to address SABA overuse, contribute to guidelines, and enhance accessibility to essential medications while engaging with pharmaceutical companies to ensure affordable access to high-quality asthma treatments. PMID: 42327548 | PMC: PMC13277371 | DOI: 10.7196/AJTCCM.2026.v32i1.4339
引用
- 指南共识 · 哮喘:South African Thoracic Society position statement on asthma in children, adolescents and adults
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。